BRIEF-Revive Therapeutics announces US FDA acceptance
July 6 (Reuters) - Revive Therapeutics Ltd :
* Revive Therapeutics Ltd announces US FDA acceptance of IND of Bucillamine for the treatment of cystinuria
* Says "look forward to initiating this phase 2 study shortly" Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.